Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01686958
Recruitment Status : Completed
First Posted : September 18, 2012
Results First Posted : October 25, 2018
Last Update Posted : June 26, 2019
Sponsor:
Information provided by (Responsible Party):
Profound Medical Inc.

Brief Summary:
This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Device: MR-Guided Transurethral US Ablation of Prostate Tissue Not Applicable

Detailed Description:

Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral ultrasound therapy system. The technology is developed for patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

The treatment is conducted completely within an MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland, thereby reducing the risk of possible damage to important surrounding anatomy such as the rectum, urinary sphincters, neurovascular bundles and pelvic bone. This coagulation method, therefore, has the potential to have lower complication rates than conventional therapies.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Actual Study Start Date : March 13, 2013
Actual Primary Completion Date : March 23, 2015
Actual Study Completion Date : June 11, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: MR-Guided Transurethral US Ablation
MR-Guided Transurethral US Ablation of Prostate Tissue
Device: MR-Guided Transurethral US Ablation of Prostate Tissue
The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
Other Name: Prostate Ablation Device: PAD-105




Primary Outcome Measures :
  1. Safety - Evaluate the Frequency of Treatment Related Adverse Events [ Time Frame: 12 months from the Treatment Date ]
    All reported adverse events were recorded. The frequency was measured as the number of study participants who experienced a treatment/device related adverse event after receiving treatment delivery with PAD-105, the investigational device.

  2. Safety - Evaluate the Severity of Treatment Related Adverse Events [ Time Frame: 12 months from the Treatment Date ]

    Severity of treatment/device related adverse events were evaluated in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) standard (version 4), published by the National Cancer Institute (NCI).

    There was no intraoperative complication, no rectal injury or fistula and no severe urinary incontinence. No Grade 4 (G4) or higher adverse events and only one attributable Grade 3 (G3) event; reported below. The common and significant Grade 1 (G1) and Grade 2 (G2) genitourinary events have also been reported.



Secondary Outcome Measures :
  1. Feasibility - Evaluate the Effectiveness of the Investigational System to Thermally Coagulate Prostate Tissue Conforming to the Target Volume With a High Degree of Accuracy and Precision [ Time Frame: On Treatment Date ]
    Conformal thermal coagulation of prostate tissue will be determined quantitatively using measures of targeting accuracy which compare the spatial difference between the target volume and target temperature isotherm determined from MR thermometry images acquired during treatment.


Other Outcome Measures:
  1. Treatment Efficacy - Biopsy [ Time Frame: 12 months from the Treatment Date ]
    Evaluate the effectiveness of the treatment to achieve disease control at 12 months based on biopsy results.

  2. Treatment Efficacy - PSA [ Time Frame: As per the Study Schedule, measured at 1-month, 3-months, 6-months and 12-months from the Treatment Date compared to Baseline ]
    Based on measurements obtained at each study visit, characterize the pattern of PSA response within the first 12 months following treatment in comparison to baseline.

  3. Treatment Efficacy - Quality of Life - Urinary Symptoms [ Time Frame: Baseline and 12-months post Treatment ]

    Evaluate quality of life in the first 12 months following Treatment compared to Baseline, using a standardized questionnaire, International Prostate Symptom Score (IPSS), which focuses on urinary symptoms.

    Total Score: 0 - 35 0-7 - mildly symptomatic 8-19 - moderately symptomatic 20-35 - severely symptomatic


  4. Treatment Efficacy - Quality of Life - Erectile Function [ Time Frame: Baseline and 12-months post Treatment ]

    Evaluate quality of life in the first 12 months following Treatment compared to Baseline, using a standardized questionnaire, Erectile Function EF domain of the International Index of Erectile Function (IIEF-15), which focuses on erectile symptoms.

    Minimum score value - 0 Maximum score value - 30 A higher score corresponds to a better outcome; lower score indicative of erectile dysfunction


  5. Treatment Efficacy - Quality of Life - Bowel Habits [ Time Frame: Baseline and 12-months post Treatment ]

    Evaluate quality of life in the first 12 months following Treatment compared to Baseline, using a standardized questionnaire, Bowel Habits domain of the UCLA Prostate Cancer Index Short Form (UCLA-PCl-SF-BH), which focuses on bowel symptoms.

    Minimum score value - 0 Maximum score value - 100 A higher score corresponds to better outcome




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 75 Years   (Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male, age ≥65
  • Patient with low-risk, early-stage organ-confined prostate cancer (Stage T1c or T2a, N0, M0).
  • Gleason score 6 (3+3)
  • Prostate-specific antigen (PSA) ≤ 10 ng/ml
  • Eligible for MR imaging (DOC-10252)
  • Meets the following criteria on pre-treatment transrectal ultrasound imaging:

    1. No cysts or calcifications > 1.0 cm in size
    2. No evidence of extraprostatic extension or seminal vesicle invasion
    3. Overall prostate size less than 5 cm in sagittal length and less than 7 cm in diameter
  • Biopsy confirmed adenocarcinoma of the prostate, performed at least 6 weeks prior to and no more than 6 months prior to the scheduled treatment.
  • Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA)
  • Normal rectal anatomy and rectal mucosa on digital rectal examination

Exclusion Criteria:

  • Bleeding disorder
  • Abnormal coagulation and current anticoagulant therapy.
  • Acute or chronic Urinary Tract Infection
  • Interest in future fertility
  • History of allergy relevant medication or other
  • History of any other malignancy other than skin cancer
  • Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome
  • Prior treatment of the prostate gland
  • Prior treatment with 5 alpha reductase inhibitor allowed (not as prostate cancer treatment or prevention) as long as drug has been stopped for minimum 3 months
  • History of any major rectal or pelvic surgery
  • History of ulcerative colitis or other chronic inflammatory conditions affecting rectum
  • History of documented clinical prostatitis requiring therapy within previous 6 months
  • History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter
  • Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic)
  • Neurologic bladder disorders
  • Untreated bladder stones
  • History of acute urinary retention
  • Confirmed or suspected bladder cancer
  • Urinary sphincter abnormalities
  • Active untreated gross hematuria for any cause
  • Post Void Residual (PVR) bladder volume > 250 mL
  • Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder

Additional exclusion criteria on file....


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01686958


Locations
Layout table for location information
United States, Michigan
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
Canada, Ontario
London Health Science Centre
London, Ontario, Canada, N6A 5W9
Germany
German Cancer Research Center (DKFZ)
Heidelberg, Germany, 69120
Sponsors and Collaborators
Profound Medical Inc.
Investigators
Layout table for investigator information
Principal Investigator: Joseph Chin, MD London Health Science Center
Principal Investigator: James Relle, MD William Beaumont Hospitals
Principal Investigator: Ryan Berglund, MD The Cleveland Clinic
Principal Investigator: Heinz P Schlemmer, MD German Cancer Research Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Profound Medical Inc.
ClinicalTrials.gov Identifier: NCT01686958     History of Changes
Other Study ID Numbers: DOC-10246
First Posted: September 18, 2012    Key Record Dates
Results First Posted: October 25, 2018
Last Update Posted: June 26, 2019
Last Verified: June 2019
Keywords provided by Profound Medical Inc.:
Prostate Cancer
High intensity transurethral ultrasound ablation
MRI-guided
Minimally invasive
Real-time temperature feedback control
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases